Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Published 12 Jun 2019

Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced upcoming presentations at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 22 – 26, 2019 in Anaheim, Ca. Highlighted presentations encompass clinical use of Axumin® (fluciclovine F 18) injection; investigational use of 18F-fluciclovine; and initial clinical experience by the Technical University of Munich with 18F-rhPSMA-7, an investigational Prostate Specific Membrane Antigen-targeted radiohybrid PET imaging agent representative of the family of rhPSMA agents that Blue Earth Diagnostics exclusively licensed in 2018.

Senior executives from Blue Earth Diagnostics will participate in sessions about advancing companies from concept to commercialization, and current and future approaches to molecular imaging and therapy. In addition, a special program led by SNMMI, “Fluciclovine Live Reader Training,” will be held immediately prior to the Annual Meeting. Details of selected oral and poster presentations by Blue Earth Diagnostics and its collaborators are listed below.

NOTE: Axumin® (fluciclovine F 18) injection is FDA-approved for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Presentations noted by “*” discuss results of investigational studies of an approved product that is not approved by the FDA for the specific use or purpose noted, or “*” denotes experience with an investigational agent for which the safety and efficacy have not been established by the FDA.

HIGHLIGHTED SCIENTIFIC PRESENTATIONS

 

Axumin (fluciclovine F 18) presentations

Date:                                   Monday, June 24, 2019

Poster Title:                       [18F]-fluciclovine positivity rate is not affected by androgen deprivation therapy (ADT) in recurrent prostate cancer post-prostatectomy

Session Title:                     MTA I: Prostate/GU Imaging Posters

Presenter:                          Olayinka Abiodun-Ojo, MD, Emory University

Presentation Time:          3:00 – 4:30 PM PT

Location:                            Exhibit Hall C

Publication No.:               1576

 

Date:                                   Monday, June 24, 2019

Poster Title:                       Comparison of 18F-Fluciclovine PET/CT and Technetium-99m MDP BS in Detection of Bone Metastasis in Prostate Cancer

Session Title:                     MTA I: Prostate/GU Imaging Posters

Presenter:                          Bo Chen, MD, MD Anderson Cancer Center

Presentation Time:          3:00 – 4:30 PM PT

Location:                            Exhibit Hall C

Publication No.:               1553

 

Investigational 18F-fluciclovine presentations

Date:                                   Monday, June 24, 2019

Session Title:                     SS47: Brain PET/MRI

Presentation Title:           Evaluation of glioma tumor volume with 18F-fluciclovine positron emission tomography interpreted in combination with MRI, compared with MRI alone: Results from a prospective phase 3 blinded image evaluation*

Presenter:                          Matthew P. Miller, PhD, Blue Earth Diagnostics

Session Time:                    4:45 – 6:15 PM PT

Presentation Time:          5:25 – 5:35 PM PT
Location:                            Room 204B

Publication No:                394

 

Date:                                   Tuesday, June 25, 2019

Session Title:                     SS58: Brain Imaging Reloaded II

Presentation Title:           Safety and effectiveness of 18F-fluciclovine PET in adults with recurrent glioma: A retrospective observational study*

Presenter:                       Tore Bach-Gansmo, MD, PhD, Oslo University Hospital

Session Time:                 10:00 – 11:30 AM PT

Presentation Time:          11:20 – 11:30 AM PT

Location:                        Room 201B

Publication No.                496

 

Date:                              Tuesday, June 25, 2019

Poster Title:                    PET imaging of recurrent brain tumors using 18F-FACBC*

Session Title:                  MTA II: Neurology & Psychiatry Imaging Posters

Presenter:                      Laure Michaud, MD, Memorial Sloan-Kettering Cancer Center

Presentation Time:          3:00 – 4:30 PM PT

Location:                        Exhibit Hall C

Publication No.:               1506

 

Date:                                Monday, June 24, 2019

Poster Title:                    [18F]-fluciclovine PET/CT is superior to conventional imaging in preoperative nodal staging in patients with high-risk prostate cancer*

Session Title:                  MTA I: Prostate/GU Imaging Posters

Presenter:                      Olayinka Abiodun-Ojo, MD, Emory University

Presentation Time:          3:00 – 4:30 PM PT

Location:                        Exhibit Hall C

Publication No.:               1580

 

Date:                                Monday, June 24, 2019

Poster Title:                      Preoperative staging in high-risk prostate cancer patients using [18F] fluciclovine PET/CT*

Session Title:                   MTA I: Prostate/GU Imaging Posters

Presenter:                       Akinyemi A. Akintayo, MD, Emory University

Presentation Time:          3:00 – 4:30 PM PT

Location:                        Exhibit Hall C

Publication No.:               1554

Date:                              Monday, June 24, 2019

Poster Title:                    [18F] Fluciclovine PET/MRI for Initial Staging of High-Risk Prostate Cancer*

Session Title:                  MTA I: Prostate/GU Imaging Posters

Presenter:                      Samuel J. Galgano, MD, University of Alabama at Birmingham

Presentation Time:          3:00 – 4:30 PM PT

Location:                        Exhibit Hall C

Publication No.:               1561

Date:                                 Tuesday, June 25, 2019

Poster Title:                       Using dynamic PET/CT imaging to explore the kinetics of 18F-fluciclovine (anti-(18)F-FACBC) in invasive breast cancer*

Session Title:                     MTA II: Data Analysis & Management Posters

Presenter:                          Nathaniel P. Scott, MSc, MPhys, University of Oxford

Presentation Time:              3:00 – 4:30 PM PT

Location:                            Exhibit Hall C

Publication No.:                   1194

 

Date:                                   Tuesday, June 25, 2019

Session Title:                     SS65: Gynecological Cancers

Presentation Title:           Feasibility of Fluciclovine PET-CT Imaging of Endometrial, Cervical and Ovarian Cancers: Preliminary Findings*

Presenter:                          Funmilayo Tade, MD, MPH, Loyola University Medical Center

Session Time:                    12:30 – 2:00 PM PT

Presentation Time:          1:50 – 2:00 PM PT

Location:                            Room 202AB

Publication No.:               558

 

Presentations on initial clinical experience with 18F-rhPSMA-7 at Technical University of Munich

Date:                                   Monday, June 24, 2019

Poster Title:                       Preclinical dosimetry and human biodistribution of 18F-rhPSMA-7 and 18F-rhPSMA-7.3*

Session Title:                     MTA I: Prostate/GU Imaging Posters

Presenter:                          So Won Oh, MD, PhD, Seoul National University Boramae Hospital

Presentation Time:          3:00 – 4:30 PM PT

Location:                            Exhibit Hall C

Publication No.:               1635

 

Date:                                   Monday, June 24, 2019

Poster Title:                       Quantitative and qualitative analysis of biodistribution and PET image quality of novel radiohybrid PSMA ligand, 18F-rhPSMA-7, in patients with prostate cancer *

Session Title:                     MTA I: Prostate/GU Imaging Posters

Presenter:                          So Won Oh, MD, PhD, Seoul National University Boramae Hospital

Presentation Time:          3:00 – 4:30 PM PT

Location:                            Exhibit Hall C

Publication No.:               1557

 

Date:                                   Monday, June 24, 2019

Poster Title:                       Histologically-confirmed diagnostic efficacy of 18F-rhPSMA-7 positron emission tomography for N-staging of patients with high risk primary prostate cancer*

Session Title:                     MTA I: Prostate/GU Imaging Posters

Presenter:                          Markus Kroenke, Technical University of Munich

Presentation Time:          3:00 – 4:30 PM PT

Location:                            Exhibit Hall C

Publication No.:               1567

 

Date:                                   Tuesday, June 25, 2019

Session Title:                     SS69: Prostate Diagnosis I

Presentation Title:           18F-rhPSMA-7 positron emission tomography (PET) for the detection of biochemical recurrence of prostate cancer following curative-intent radiation therapy*

Presenter:                          Harun Ilhan, MD, Ludwig-Maximilian-University (LMU), Munich 

Session Time:                    12:30 – 2:00 PM PT

Presentation Time:          1:30 – 1:40 PM PT

Location:                            204B

Publication No.:               592

 

Date:                                   Tuesday, June 25, 2019

Session Title:                     SS76: Prostate Cancer Diagnosis II

Presentation Title:           18F-rhPSMA-7 positron emission tomography (PET) for the detection of biochemical recurrence of prostate cancer following radical prostatectomy*

Presenter:                          Matthias Eiber, MD, Technical University of Munich

Session Time:                    10:00 – 11:30 AM PT

Presentation Time:          11:20 11:30 AM PT

Location:                            Room 204B

Publication No.:               649

PANEL PRESENTATIONS

 

Date:                                   Saturday, June 22, 2019

Session Title:                     Concept to Commercialization and Funding Along the Way

Panel Title:                        Emerging Technologies, Funding, M&A

Panel Participant:             Jonathan Allis, D.Phil., CEO, Blue Earth Diagnostics

Session Time:                    Saturday 3:30 – 5

Location:                            Room 303AB

 

Date:                                   Sunday, June 23, 2019

Session Title:                     CMIIT Emerging Technologies – Emerging Technologies – A Look into the Future of Molecular Imaging and Therapy

Presentation Title:           Molecular Imaging and Therapy – Current and Future Approaches*

Presenter:                          David Gauden, D.Phil., CSO, Blue Earth Diagnostics

Session Time:                    4:30 – 6:00 PM PT

Presentation Time:          4:30 – 4:50 PM PT
Location:                            Room 201D

In addition, the following presentations will be part of independent continuing education programs at SNMMI.

 

Date:                                   Saturday, June 22, 2019

Session Title:                     SNMMI Special Programming

Presentation Title:           Fluciclovine Live Training Session

Session Time:                    9:00 AM PT – 12:00 PM PT

Location:                            Registration required: http://www.snmmi.org/AM/Registration/RegistrationAM.aspx

Date:                                   Saturday, June 22, 2019

Session Title:                     CE08: Prostate Cancer Nuts and Bolts: Diagnosis and Therapy

Presentation Title:           Prostate Cancer Diagnostic: Fluciclovine F18 PET/CT

Presenter:                          David M. Schuster, MD, Emory University

Session Time:                    3:15 – 4:45 PM PT

Presentation Time:          3:15 – 3:45 PM PT

Location:                            Room 211AB

Date:                                   Sunday, June 23, 2019

Session Title:                     CE29: New PET Radiopharmaceuticals – Read with the Experts

Presentation Title:           Fluciclovine F18 PET/CT

Presenter:                          David M. Schuster, MD, Emory University

Session Time:                    4:45 – 6:15 PM PT

Presentation Time:          4:45 – 5:05 PM PT

Location:                            Room 212AB

Blue Earth Diagnostics invites participants at this year’s SNMMI Annual Meeting to attend the presentations above and to visit the company at Exhibit Booth 720.

Syncona Limited Disclaimer

Please read the below disclaimer carefully. You will be asked to accept these terms and conditions before proceeding.

The information on this website is directed only at persons who are shareholders in Syncona Limited (the “Company”) and is provided for their exclusive use and benefit.

Users of this website are responsible for observing all applicable laws and regulations in their relevant jurisdictions before proceeding to access the information contained herein. By proceeding to access the information, users are deemed to be representing and warranting that the applicable laws and regulations of their relevant jurisdiction allow them to do so. No information, materials or opinions contained on this website (“Materials”) constitute or would be deemed to constitute a recommendation or invitation in any jurisdiction to invest or otherwise deal in the shares of the Company (the “Shares”).

The website that you are seeking to access does not constitute an offer to buy or sell the securities mentioned in the website in any jurisdiction or jurisdictions in which such offers or sales are unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In particular, the securities mentioned in the website have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or exemption from registration under the Securities Act and other securities laws. There will be no public offer of these securities in the United States. Offers and sales of these securities, and distribution of the related information, may also be subject to restrictions in other jurisdictions.

The website that you are seeking to access is not directed at and may not be viewed by or distributed to persons:

  • in the United States or who are U.S persons (as defined in Rule 902 under the Securities Act);

or

  • located in a jurisdiction where it is not lawful to access the materials.

The Materials are provided on an “as is” and “as available basis” and do not purport to be full or complete. The Company and its affiliates believe that the source of the Materials is reliable however they cannot and do not guarantee, either expressly or implicitly, and accept no liability for, the accuracy, validity, timeliness, merchantability or completeness of any information or data (whether prepared by the Company, its affiliates or by any third party) for any particular purpose or use or that the information or data will be free from error. The Company and its affiliates do not undertake any responsibility for any reliance which is placed by any person on any statements or opinions which are expressed herein. Neither the Company, nor any of its affiliates, directors, officers or employees will be liable or have any responsibility of any kind for any loss or damage that any person may incur resulting from the use of this information.Nothing contained in this website constitutes financial, investment, legal, tax or other advice and is not to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision.

The Materials on this website are provided for your personal use and informational purposes only and are subject to change without notice. The Company has the right to suspend or withdraw the provision of all or any of the website of the Materials without prior notice at any time.

The value of investments mentioned in this site, and the income from them may go down as well as up and investors may not get back the amount invested. Information on past performance, where given, is not a guide to future performance. Changes in rates of exchange between currencies may cause the value of investments to decrease or increase.
The Company is a registered closed-ended collective investment scheme registered pursuant to the Protection of Investors (Bailiwick of Guernsey) Law, 1987, as amended (the ‘‘POI Law’’) and the Registered Collective Investment Scheme Rules 2008 (the ‘‘CIS Rules’’) issued by the Guernsey Financial Services Commission (the ‘‘GFSC’’). Neither the GFSC nor the States of Guernsey Policy Council take any responsibility for the financial soundness of the Company or for the correctness of any of the statements made or opinions expressed with regard to it.

Copyright

Copyright of all images and text in this website is owned by or licensed to the Company or one of its affiliates unless otherwise noted. You may imprint, copy, download or temporarily store extracts from this website for your personal information and use. Any other use is prohibited unless you first request and obtain the prior written consent of the Company. You may not alter or otherwise make any changes to any material that you print or download from this website, including, without limitation, removing any identifying marks or legends from such material. In particular, you may not copy or use any part of this website on any other website, or link any other website to this website, without the prior written permission of the Company. You may not use the website for any purpose which is unlawful, abusive, libellous, obscene or threatening.

No Warranty

The Materials contained in this website are provided without any warranty of any kind, either expressed or implied, to the fullest extent permissible pursuant to applicable law. Neither the Company nor its affiliates assume any responsibility for the uninterrupted availability of this website or warrant that it will be error-free, that defects will be corrected, or that this website or the servers that make it available will be free of viruses or other harmful components.

Liability Waiver

You agree that under no circumstances, including, but not limited to, negligence, shall the Company or any of its affiliates be liable for any special or consequential damages that result from the access or use of, or the inability to access or use, the Materials on this website. This does not exclude or restrict any duty or liability that the Company has to its customers under the regulatory system in the United Kingdom or Guernsey.

Privacy Policy

This policy sets out what the Company and its affiliates do with any personal information collected from this website.

Any personal information collected from this website will be processed in accordance with relevant data protection laws.

You may use the public areas of this website without providing the Company or its affiliates with any personal information and the Company and its affiliates do not monitor or collect any personal information through your access to the public areas of this website. The Company and its affiliates do not use cookies to collect information but may gather other anonymous information to assist in improving the services.

If you chose to provide the Company and its affiliates with personal information, this information will only be used for the purposes of the service that you have requested. The Company and its affiliates will not sell or transfer any personal information to third parties without your permission, other than as required by law.

The Company and its affiliates are not responsible for the content or privacy policies of websites to which this website may link.

The Company and its affiliates are committed to protecting your personal information but in the event that the system is infiltrated by unauthorised third parties the Company and its affiliates will not be liable for any resulting misuse of personal information.

Linked Sites

The Company has not reviewed any website linked to this website and is not responsible for the contents of off-site pages or any other websites linked or linking to this website. If you follow any links from this website you do so at your own risk.

Links to this website may not be established without the prior written consent of the Company.

Governing Law

The terms and conditions of this legal notice shall be governed by and construed in accordance with the laws of Guernsey. Users of this website agree that any dispute or action arising out of or relating to these terms or any user’s use of this website shall be commenced only in the courts located in Guernsey, and users of this website hereby consent and submit to the exclusive jurisdiction of such courts for the purposes of any such dispute or action.

By accessing Materials on this website you agree to be bound by the foregoing limitations.